Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.25.

Several analysts have commented on the company. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Raymond James Financial started coverage on Milestone Pharmaceuticals in a research note on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price objective for the company. Zacks Research downgraded Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th. Finally, Wells Fargo & Company cut their target price on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th.

Insiders Place Their Bets

In related news, CEO Joseph Oliveto sold 36,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $2.26, for a total value of $82,490.00. Following the completion of the transaction, the chief executive officer directly owned 446,244 shares of the company’s stock, valued at $1,008,511.44. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently bought and sold shares of MIST. Propel Bio Management LLC increased its stake in Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after purchasing an additional 3,333,333 shares in the last quarter. Orbimed Advisors LLC purchased a new position in Milestone Pharmaceuticals in the 3rd quarter valued at approximately $6,444,000. Marshall Wace LLP increased its stake in Milestone Pharmaceuticals by 289.8% in the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after purchasing an additional 1,231,793 shares in the last quarter. Pathstone Holdings LLC purchased a new position in Milestone Pharmaceuticals in the 3rd quarter valued at approximately $2,000,000. Finally, Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals in the 3rd quarter valued at approximately $1,333,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Stock Down 7.2%

MIST opened at $1.41 on Tuesday. The business has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $1.91. The company has a quick ratio of 9.09, a current ratio of 9.18 and a debt-to-equity ratio of 1.61. The company has a market cap of $175.54 million, a PE ratio of -2.07 and a beta of 1.04. Milestone Pharmaceuticals has a 52 week low of $1.00 and a 52 week high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.26). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.12 million. As a group, research analysts anticipate that Milestone Pharmaceuticals will post -0.97 EPS for the current year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.